ACET

SEC source: 0000899243-20-025647 · doc4.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 872,111

Underlying: Common Stock · 872,111 shares

Expires 2030-09-16

F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries.

SEC source: 0000947871-20-000740 · ownership.xml · derivative · entry 3

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-17

F6 · derivative.exercise_date: This option was granted on September 17, 2020 with respect to 30,000 shares of Common Stock. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II.

F6 · ownership.direct: This option was granted on September 17, 2020 with respect to 30,000 shares of Common Stock. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II.

SEC source: 0000899243-20-025646 · doc4.xml · derivative · entry 3

ABBOT STEWART · CIK 0001655597 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,751

Underlying: Common Stock · 63,751 shares

Expires 2030-09-17

F5 · derivative.exercise_date: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Abbot remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025644 · doc4.xml · derivative · entry 3

Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,391

Underlying: Common Stock · 40,391 shares

Expires 2030-09-17

F5 · derivative.exercise_date: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025645 · doc4.xml · derivative · entry 1

Chodakewitz Jeffrey · CIK 0001610876 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F1 · derivative.exercise_date: This option shall vest as follows: 1/36th of the shares shall vest on each of the next thirty-six (36) monthly anniversaries of the Vesting Commencement Date.

SEC source: 0000899243-20-025640 · doc4.xml · derivative · entry 2

Galimi Francesco · CIK 0001823996 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,269

Underlying: Common Stock · 77,269 shares

Expires 2030-09-16

F3 · derivative.exercise_date: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.

SEC source: 0000947871-20-000737 · ownership.xml · derivative · entry 5

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-17

F9 · derivative.exercise_date: This option was granted on September 17, 2020 with respect to 30,000 shares of Common Stock. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefit are provided to OPI V and OPI VI.

F9 · ownership.direct: This option was granted on September 17, 2020 with respect to 30,000 shares of Common Stock. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefit are provided to OPI V and OPI VI.

SEC source: 0000947871-20-000738 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 292,607

F7 · price: Received in exchange for 2,359,734 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2.

F4 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon ("Gordon") and Erez Chimovits ("Chimovits") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F8 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.

SEC source: 0000947871-20-000738 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 902,855

F5 · price: Received in exchange for 7,281,335 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2.

F4 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon ("Gordon") and Erez Chimovits ("Chimovits") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F6 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.

SEC source: 0000947871-20-000738 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,822,960

F2 · price: Received in exchange for 38,894,843 shares of the common stock of Adicet Bio, Inc., ("Old Adicet") on the closing of the merger (the "Merger") pursuant to the Agreement and Plan of Merger dated April 18, 2020 (the "Merger Agreement") by and among the Issuer, Old Adicet and Project Oasis Merger Sub, Inc., a direct, wholly-owned subsidiary of the Issuer, whereby each share of Old Adicet common stock was canceled and automatically converted into .1240 shares of Issuer common stock (the "Exchange Ratio"), with fractional shares being eliminated after first being aggregated, as provided in the Merger Agreement. The Issuer was renamed Adicet Bio, Inc. following the closing of the Merger.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F4 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon ("Gordon") and Erez Chimovits ("Chimovits") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-20-025654 · doc4.xml · nonDerivative · entry 1

Schindel Yair Chaim · CIK 0001823758 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By aMoon 2 Fund Limited Partnership

Disclosed balance after: 1,104,460

F1 · shares: The reporting person is the sole shareholder of aMoon General Partner Ltd., which is the sole general partner of aMoon 2 Fund G.P. Limited Partnership, which is the sole general partner of aMoon 2 Fund Limited Partnership, which directly holds the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F2 · price: Received in exchange for shares of Series B Preferred Stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, the closing share price of a share of resTORbio common stock was $2.28 per share. On the effective date of the Merger, resTorbio changed its name to "Adicet Bio, Inc."

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained irrevocable trust.

Disclosed balance after: 77,500

F3 · price: Received in exchange for 625,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F7 · ownership.nature: Shares held in a trust of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits's child is the beneficiary.

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained irrevocable trust.

Disclosed balance after: 77,500

F3 · price: Received in exchange for 625,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F6 · ownership.nature: Shares held in a trust of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits's child is the beneficiary.

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained annuity trust.

Disclosed balance after: 135,799

F2 · price: Received in exchange for 1,095,154 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F5 · ownership.nature: Shares held in a GRAT of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained annuity trusts.

Disclosed balance after: 627,812

F1 · price: Received in exchange for 5,063,006 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F4 · ownership.nature: Shares held in a grantor retained annuity trust ("GRAT") of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.

SEC source: 0000947871-20-000740 · ownership.xml · nonDerivative · entry 2

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 292,607

F3 · price: Received in exchange for 2,359,734 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2.

F4 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II.

F5 · ownership.nature: Each of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000740 · ownership.xml · nonDerivative · entry 1

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 902,855

F1 · price: Received in exchange for 7,281,335 shares of the common stock of Adicet Bio, Inc., ("Old Adicet") on the closing of the merger (the "Merger") pursuant to the Agreement and Plan of Merger dated April 18, 2020 (the "Merger Agreement") by and among the Issuer, Old Adicet and Project Oasis Merger Sub, Inc., a direct, wholly-owned subsidiary of the Issuer, whereby each share of Old Adicet common stock was canceled and automatically converted into .1240 shares of Issuer common stock (the "Exchange Ratio"), with fractional shares being eliminated after first being aggregated, as provided in the Merger Agreement. The Issuer was renamed Adicet Bio, Inc. following the closing of the Merger.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP.

F5 · ownership.nature: Each of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-20-025646 · doc4.xml · derivative · entry 2

ABBOT STEWART · CIK 0001655597 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,151

Underlying: Common Stock · 57,151 shares

Expires 2029-10-15

F4 · price: Received in exchange for an employee stock option to acquire 460,900 shares of common stock of Old Adicet for $0.740 per share in connection with the Merger.

F3 · derivative.exercise_date: 1/48th of the option vests on each of the forty-eight (48) monthly anniversaries of October 15, 2019, provided that Dr. Abbot remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025646 · doc4.xml · derivative · entry 1

ABBOT STEWART · CIK 0001655597 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,791

Underlying: Common Stock · 84,791 shares

Expires 2028-08-14

F2 · price: Received in exchange for an employee stock option to acquire 683,800 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.280 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F1 · derivative.exercise_date: 25% of the option vested on June 27, 2019, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Abbot remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025644 · doc4.xml · derivative · entry 2

Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,450

Underlying: Common Stock · 15,450 shares

Expires 2029-10-15

F4 · price: Received in exchange for an employee stock option to acquire 124,600 shares of common stock of Old Adicet for $0.740 per share in connection with the Merger.

F3 · derivative.exercise_date: 1/48th of the option vests on each of the forty-eight (48) monthly anniversaries of October 15, 2019, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025644 · doc4.xml · derivative · entry 1

Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,600

Underlying: Common Stock · 18,600 shares

Expires 2027-12-13

F2 · price: Received in exchange for an employee stock option to acquire 150,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.280 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F1 · derivative.exercise_date: 25% of the option vested on November 27, 2018, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025640 · doc4.xml · derivative · entry 1

Galimi Francesco · CIK 0001823996 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,424

Underlying: Common Stock · 128,424 shares

Expires 2029-10-15

F2 · price: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F1 · derivative.exercise_date: 25% of the option will vest on September 23, 2020, and 1/36th of the remaining unvested option will vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.

SEC source: 0000947871-20-000737 · ownership.xml · nonDerivative · entry 4

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 292,607

F6 · price: Received in exchange for 2,359,734 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2.

F7 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of the Reporting Person, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.

F8 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000737 · ownership.xml · nonDerivative · entry 3

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 902,855

F4 · price: Received in exchange for 7,281,335 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2.

F5 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of the Reporting Person, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.

F8 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000737 · ownership.xml · nonDerivative · entry 2

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,822,960

F2 · price: Received in exchange for 38,894,843 shares of the common stock of Adicet Bio, Inc., ("Old Adicet") on the closing of the merger (the "Merger") pursuant to the Agreement and Plan of Merger dated April 18, 2020 (the "Merger Agreement") by and among the Issuer, Old Adicet and Project Oasis Merger Sub, Inc., a direct, wholly-owned subsidiary of the Issuer, whereby each share of Old Adicet common stock was canceled and automatically converted into .1240 shares of Issuer common stock (the "Exchange Ratio"), with fractional shares being eliminated after first being aggregated, as provided in the Merger Agreement. The Issuer was renamed Adicet Bio, Inc. following the closing of the Merger.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F8 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-20-015455 · doc4.xml · derivative · entry 1

SILVERSTEIN JONATHAN · CIK 0001171005 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-20-015458 · doc4.xml · derivative · entry 1

Grissinger Michael · CIK 0001757601 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-20-015456 · doc4.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-20-015454 · doc4.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-20-015450 · doc4.xml · derivative · entry 1

Steinberg David Adam · CIK 0001727735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-20-015447 · doc4.xml · derivative · entry 1

Chodakewitz Jeffrey · CIK 0001610876 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-19-029671 · doc4.xml · nonDerivative · entry 1

PureTech Health LLC · CIK 0001727395 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,119,696

SEC source: 0000899243-19-029467 · doc4.xml · nonDerivative · entry 1

PureTech Health LLC · CIK 0001727395 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,281,227

F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.24 to $1.25, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000899243-19-029074 · doc4.xml · nonDerivative · entry 3

PureTech Health LLC · CIK 0001727395 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,486,990

F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.24 to $1.265, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000899243-19-029074 · doc4.xml · nonDerivative · entry 2

PureTech Health LLC · CIK 0001727395 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,872,874

F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.255, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000899243-19-029074 · doc4.xml · nonDerivative · entry 1

PureTech Health LLC · CIK 0001727395 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,932,795

F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.29, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000899243-19-028706 · doc4.xml · derivative · entry 2

MCCABE JOHN J · CIK 0001205535 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,400

Underlying: Common Stock · 16,400 shares

Expires 2029-12-05

F2 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-19-028706 · doc4.xml · nonDerivative · entry 1

MCCABE JOHN J · CIK 0001205535 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,867

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000899243-19-028707 · doc4.xml · derivative · entry 3

Mannick Joan · CIK 0001727384 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,667

Underlying: Common Stock · 88,667 shares

Expires 2029-12-05

F3 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-19-028707 · doc4.xml · nonDerivative · entry 1

Mannick Joan · CIK 0001727384 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404,585

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000899243-19-028705 · doc4.xml · derivative · entry 2

Klickstein Lloyd · CIK 0001776004 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,667

Underlying: Common Stock · 88,667 shares

Expires 2029-12-05

F2 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-19-028705 · doc4.xml · nonDerivative · entry 1

Klickstein Lloyd · CIK 0001776004 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,222

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000899243-19-028704 · doc4.xml · derivative · entry 3

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,000

Underlying: Common Stock · 258,000 shares

Expires 2029-12-05

F3 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-19-028704 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 669,000

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000899243-21-012680 · doc4.xml · nonDerivative · entry 1

Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,888

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance

F2 · shares: The amount of securities reported herein have been adjusted to reflect the 1-for-7 reverse stock split that was effected in September 2020 in connection with the merger of resTORbio, Inc. and Adicet Therapeutics, Inc., formerly known as Adicet Bio, Inc.

F2 · balance_after: The amount of securities reported herein have been adjusted to reflect the 1-for-7 reverse stock split that was effected in September 2020 in connection with the merger of resTORbio, Inc. and Adicet Therapeutics, Inc., formerly known as Adicet Bio, Inc.

SEC source: 0000899243-19-027581 · doc4.xml · nonDerivative · entry 1

PureTech Health LLC · CIK 0001727395 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,269,356

F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.43, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000899243-19-013558 · doc4.xml · derivative · entry 1

Klickstein Lloyd · CIK 0001776004 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,000

Underlying: Common Stock · 295,000 shares

Expires 2029-05-12

F1 · derivative.exercise_date: 25% of the shares shall vest on May 13, 2020, and the remaining shares shall vest in 12 equal quarterly installments thereafter.

SEC source: 0000899243-19-012924 · doc4.xml · derivative · entry 1

SILVERSTEIN JONATHAN · CIK 0001171005 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2029-05-07

F1 · derivative.exercise_date: This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-19-012923 · doc4.xml · derivative · entry 1

Grissinger Michael · CIK 0001757601 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2029-05-07

F1 · derivative.exercise_date: This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-19-012919 · doc4.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Stock · 14,414 shares

Expires 2029-05-07

F1 · derivative.exercise_date: This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.